MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Sees Significant Decline in Short Interest

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) saw a large drop in short interest in March. As of March 13th, there was short interest totaling 332,123 shares, a drop of 32.1% from the February 26th total of 489,206 shares. Approximately 0.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 169,231 shares, the short-interest ratio is presently 2.0 days.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of MIRA Pharmaceuticals by 100.0% in the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after acquiring an additional 136,438 shares during the period. Fifth Third Bancorp bought a new stake in shares of MIRA Pharmaceuticals in the fourth quarter worth about $30,000. First American Bank lifted its holdings in MIRA Pharmaceuticals by 20.0% in the 4th quarter. First American Bank now owns 60,000 shares of the company’s stock worth $91,000 after buying an additional 10,000 shares during the period. Two Sigma Investments LP lifted its holdings in MIRA Pharmaceuticals by 129.8% in the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after buying an additional 25,816 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of MIRA Pharmaceuticals in the 2nd quarter worth approximately $26,000. Hedge funds and other institutional investors own 35.16% of the company’s stock.

Wall Street Analyst Weigh In

MIRA has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Monday, December 29th. Rodman & Renshaw started coverage on shares of MIRA Pharmaceuticals in a report on Tuesday, January 13th. They issued a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

MIRA Pharmaceuticals Stock Performance

MIRA traded down $0.03 on Friday, hitting $1.03. 109,033 shares of the company were exchanged, compared to its average volume of 188,683. The firm has a fifty day simple moving average of $1.22 and a two-hundred day simple moving average of $1.37. The stock has a market capitalization of $43.14 million, a PE ratio of -0.67 and a beta of 1.78. MIRA Pharmaceuticals has a 12 month low of $0.73 and a 12 month high of $2.45.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.